GPCR · Insider Trading
Structure Therapeutics Inc. American Depositary Shares
Every open-market purchase and sale reported by GPCR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-22 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | MIXED | −22,650 | −$124.01K |
| 2026-09-02 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | +$6.06K |
| 2026-08-19 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | +$4.02K |
| 2026-08-07 | John Joseph Berrios | Chief Commercial Officer | A | +140,766 | — |
| 2026-08-07 | John Joseph Berrios | Chief Commercial Officer | A | +140,766 | — |
| 2026-08-05 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | +$4.02K |
| 2026-07-24 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2026-07-15 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | +$8.04K |
| 2026-06-29 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | +$8.04K |
| 2026-06-18 | Joanne Waldstreicher | Director | A | +39,453 deriv. | — |
| 2026-06-18 | Daniel G Welch | Director | A | +39,453 deriv. | — |
| 2026-06-18 | Ted W Love | Director | A | +39,453 deriv. | — |
| 2026-06-18 | Eric Dobmeier | Director | A | +39,453 deriv. | — |
| 2026-06-18 | Angus C. Russell | Director | A | +39,453 deriv. | — |
| 2026-06-18 | Sharon Tetlow | Director | A | +39,453 deriv. | — |
| 2026-04-23 | Matthew Lang | COO & GC | A | +184,614 | — |
| 2026-04-16 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2026-03-23 | Ashley Hall | Chief Development Officer | A | +47,706 | — |
| 2026-03-23 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | A | +75,897 | — |
| 2026-03-23 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | A | +43,368 | — |
| 2026-03-23 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | A | +32,526 | — |
| 2026-03-23 | Jun Yoon | CHIEF FINANCIAL OFFICER | A | +104,085 | — |
| 2026-03-23 | Raymond C Stevens | CHIEF EXECUTIVE OFFICER | A | +260,217 | — |
| 2026-03-05 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | F | −18,735 | −$393.25K |
| 2026-03-05 | Jun Yoon | CHIEF FINANCIAL OFFICER | F | −22,305 | −$468.18K |
| 2026-03-05 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | F | −11,826 | −$248.23K |
| 2026-03-05 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | F | −11,313 | −$237.46K |
| 2026-03-05 | Raymond C Stevens | CHIEF EXECUTIVE OFFICER | F | −53,454 | −$1.12M |
| 2026-03-05 | Ashley Hall | Chief Development Officer | F | −4,836 | −$101.51K |
| 2026-01-20 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-12-10 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-09-22 | Ashley Hall | Chief Development Officer | F | −6,021 | −$46.62K |
| 2025-09-22 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | F | −8,106 | −$62.77K |
| 2025-08-20 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | F | −4,470 | −$30.56K |
| 2025-08-20 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | F | −12,846 | −$87.82K |
| 2025-08-01 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-07-03 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | MIXED | +22,635 | −$14.44K |
| 2025-07-03 | Raymond C Stevens | CHIEF EXECUTIVE OFFICER | MIXED | +61,152 | −$208.65K |
| 2025-07-03 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | +50,637 | −$50.99K |
| 2025-07-03 | Jun Yoon | CHIEF FINANCIAL OFFICER | MIXED | +26,577 | −$95.49K |
| 2025-07-03 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | MIXED | +5,325 | −$19.56K |
| 2025-06-25 | Sharon Tetlow | Director | A | +51,804 deriv. | — |
| 2025-06-25 | Eric Dobmeier | Director | A | +51,804 deriv. | — |
| 2025-06-25 | Joanne Waldstreicher | Director | A | +51,804 deriv. | — |
| 2025-06-25 | Ted W Love | Director | A | +51,804 deriv. | — |
| 2025-06-25 | Daniel G Welch | Director | A | +51,804 deriv. | — |
| 2025-06-25 | Angus C. Russell | Director | A | +42,833 deriv. | — |
| 2025-03-18 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | A | +80,829 | — |
| 2025-03-18 | Crespo Blas Coll | Chief Medical Officer | A | +116,988 | — |
| 2025-03-18 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | A | +63,810 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jun Yoon | CHIEF FINANCIAL OFFICER | 2,956,242 | $65.07M |
| Raymond C Stevens | CHIEF EXECUTIVE OFFICER | 2,956,179 | $65.07M |
| Crespo Blas Coll | CHIEF MEDICAL OFFICER | 270,252 | $5.95M |
| FMR LLC | 10%+ Owner | 241,275 | $5.31M |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 228,960 | $5.04M |
| Matthew Lang | COO & GC | 184,614 | $4.06M |
| Ashley Hall | Chief Development Officer | 155,187 | $3.42M |
| John Joseph Berrios | Chief Commercial Officer | 140,766 | $3.10M |
| Yingli Ma | CHIEF TECHNOLOGY OFFICER | 139,917 | $3.08M |
| Daniel G Welch | Director | 123,508 | $2.72M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GPCR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.